ESI-MS characterisation of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes

被引：87

作者：

Casini, Angela

Mastrobuoni, Guido

Ang, Wee Han

Gabbiani, Chiara

Pieraccini, Giuseppe

Moneti, Gloriano

Dyson, Paul J.

Messori, Luigi

机构：

[1] Department of Chemistry, University of Florence, 50019 Sesto Fiorentino

[2] Mass Spectrometry Centre, University of Florence, 50019 Sesto Fiorentino

[3] Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL)

来源：

CHEMMEDCHEM | 2007年 / 2卷 / 05期

关键词：

D O I：

10.1002/cmdc.200600258

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Electrospray ionization mass spectrometry allows a rapid characterisation of the adducts formed between three novel anticancer ruthenium(II)-arene PTA compounds and horse heart cytochromec or hen egg white lysozyme. Specific information on the nature of the protein-bound metallic fragments and the extent of protein metallation was readily obtained.

引用

收藏

页码：631 / +

页数：6

相关论文

共 28 条

[1] Ruthenium antimetastatic agents [J].

Alessio, E ;

Mestroni, G ;

Bergamo, A ;

Sava, G .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (15) :1525-1535

[2] [Ru(η6-p-cymene)Cl2(pta)] (pta=1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane):: a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells [J].

Allardyce, CS ;

Dyson, PJ ;

Ellis, DJ ;

Heath, SL .

CHEMICAL COMMUNICATIONS, 2001, (15) :1396-1397

[3] Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis [J].

Ang, Wee Han ;

Daldini, Elisa ;

Scolaro, Claudine ;

Scopelliti, Rosario ;

Juillerat-Jeannerat, Lucienne ;

Dyson, Paul J. .

INORGANIC CHEMISTRY, 2006, 45 (22) :9006-9013

[4] Classical and non-classical ruthenium-based anticancer drugs: Towards targeted chemotherapy [J].

Ang, Wee Han ;

Dyson, Paul J. .

EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, 2006, (20) :4003-4018

[5]

Barnes KR, 2004, MET IONS BIOL SYST, V42, P143

[6] Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin [J].

Bergamo, A ;

Messori, L ;

Piccioli, F ;

Cocchietto, M ;

Sava, G .

INVESTIGATIONAL NEW DRUGS, 2003, 21 (04) :401-411

[7] Exploring metallodrug-protein interactions by ESI mass spectrometry: The reaction of anticancer platinum drugs with horse heart cytochrome c [J].

Casini, Angela ;

Gabbiani, Chiara ;

Mastrobuoni, Guido ;

Messori, Luigi ;

Moneti, Gloriano ;

Pieraccini, Giuseppe .

CHEMMEDCHEM, 2006, 1 (04) :413-417

[8] ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme [J].

Casini, Angela ;

Mastrobuoni, Guido ;

Temperini, Claudia ;

Gabbiani, Chiara ;

Francese, Simona ;

Moneti, Gloriano ;

Supuran, Claudiu T. ;

Scozzafava, Andrea ;

Messori, Luigi .

CHEMICAL COMMUNICATIONS, 2007, (02) :156-158

[9] Binding of organometallic ruthenium(II) and osmium(II) complexes to an oligonucleotide: A combined mass spectrometric and theoretical study [J].

Dorcier, A ;

Dyson, PJ ;

Gossens, C ;

Rothlisberger, U ;

Scopelliti, R ;

Tavernelli, I .

ORGANOMETALLICS, 2005, 24 (09) :2114-2123

[10] Metal-based antitumour drugs in the post genomic era [J].

Dyson, PJ ;

Sava, G .

DALTON TRANSACTIONS, 2006, (16) :1929-1933